Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Breast Cancer Female Clinical Trial

Official title:

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03969121
• Other study ID #: OOTR-N016/KBCRN-B-003/HT-PAB
• Status: Completed
• Phase: Phase 3
• Start date: July 16, 2019
• Est. completion date: December 23, 2021

Study information

• Verified date: June 2021
• Source: Kyoto Breast Cancer Research Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the efficacy of palbociclib in combination with Endocrine therapy over Endocrine therapy alone measured by PEPI and EndoPredict™ EPclin Score in women with operable HR+, HER2 negative breast cancer . The Clinical Response Rate, drop in Ki67 index ≤ 2.7% and Breast conserving rate will be compared between two arms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 141
• Est. completion date: December 23, 2021
• Est. primary completion date: December 23, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Pre/peri- or post-menopausal women 18 years and older (or local legal age, whichever is higher)

2. Primary tumor greater than 15 mm in diameter

3. Histologically proven invasive breast cancer

4. Positive hormone receptor (ER and/or PgR =1% in proportion of positive staining score)

5. Negative HER-2 receptor (based on 2018 ASCO/CAP Guideline)

6. Ki67 index equal to or greater than 14% (Ki67 = 14%) by central assessment using actual or virtual slides

7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) = 1

8. No previous history of radiotherapy or systemic therapy including chemotherapy and hormone therapy for breast cancer

9. Laboratory values must be as follows:

Absolute neutrophil count: = 1,500/mm3 Platelets: = 100,000/mm3 Hemoglobin: = 9 g/dL Bilirubin: = 1.5 × upper limits of normal (ULN) Serum Creatinine: = 1.5 × ULN Alkaline phosphatase: = 2 × ULN AST and ALT: = 2 × ULN Cardiac function: Normal finding of Electrocardiogram (ECG) QTc = 480 msec (based on the mean value of the triplicate ECGs).

10. Able to give written informed consent form

11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

1. Male

2. Locally advanced breast cancer ( Any T4 or Any N2, N3), or distant metastasis

3. Multicentric breast cancer (Note: Multifocal breast cancer,located in one quadrant/are is eligible)

4. Prior treatment with chemotherapy, radiotherapy and/or endocrine therapy

5. Previous use of SERMs such as raloxifene.

6. Prior therapy with any CDK4/6 inhibitor or with everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway.

7. Prior history of other malignancy within 5 years of study entry, aside from basal cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix

8. Major surgery within 3 weeks of first study treatment

9. Patients treated within the last 7 days prior to randomization with:

• Food or drugs that are known strong and moderate CYP3A4 inhibitors (e.g., amprenavir, aprepitant, atazanavir, boceprevir, casopitant, cimetidine, ciprof-loxacin, clarithromycin, conivaptan, cobicistat, crizotinib, cyclosporine, da-runavir, diltiazem, dronedarone, elvitegravir, erythromycin, fluconazole, fosamprenavir, imatinib, indinavir, isavuconazole, istradefylline, itraconazole,ketoconazole, letermovir, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, nilotinib, posaconazole, ritonavir, saquinavir, schisandra sphenan-thera extract, telaprevir, telithromycin, tofisopam, verapamil, voriconazole, and grapefruit, grapefruit juice or any product containing grapefruit);
• Drugs that are known strong and moderate CYP3A4 inducers (e.g., bosentan, carbamazepine, efavirenz, etravirine, modafinil, phenobarbital, phenytoin, ri-fampin, rifapentin, and St. John's wort);

10. Any of the following in the previous 6 months of randomization: myocardial in-farction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE version 4.03 grade = 2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident in-cluding transient ischemic attack, or symptomatic pulmonary embolism

11. Family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP).

12. Uncontrolled electrolyte disorders (eg, hypocalcemia, hypokalemia, hypomag-nesemia) that can compound the effects of a QTc-prolonging drug.

13. Active inflammatory bowel disease or chronic diarrhea. Short bowel syndrome. Upper gastrointestinal surgery including gastric resection.

14. Prior hematopoietic stem cell or bone marrow transplantation.

15. Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding subcutaneous injections of leuprorelin or goserelin.

16. Hepatitis B and/or hepatitis C carriers (Patients with HBsAg+ or HBV-DNA+ who need antiviral treatment during any anti-cancer therapy based on guidelines are excluded even if the patient's hepatic function is normal. Patients with HCVAb+, whose HCV-RNA is positive (+) are excluded.)

17. Known human immunodeficiency virus (HIV) infection

18. Known hypersensitivity to anti-aromatase drugs, tamoxifen or any cell cycle in-hibitor.

19. Patients who are pregnant or lactating. Patients of childbearing potential and/or her partner who are unwilling or unable to use a method of highly effective non-hormonal contraception throughout the study and continue for at least 21 days in patients after the last dose of investigational drug.

20. Other severe acute or chronic medical or psychiatric condition, or laboratory ab-normality that would impart, in the judgment of the investigator, excess risk as-sociated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study

21. Patients who are investigational site staff members or relatives of those site staff OOTR-N016/KBCRN-B-003/HT-PAB Protocol (version 1.2 dated Oct 11, 2018) 24 members or patients who are the sponsor employees directly involved in the con-duct of the trial.

22. Participation in other studies involving investigational drug (s) (Phases 1-4) within 2 weeks before randomization and/or until a visit at 4 weeks (+7 days) after operation.

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms
• Hormone Receptor Positive Malignant Neoplasm of Breast
• Neoplasms

Intervention

Drug:
• Palbociclib
Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
• Endocrine therapy
Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.

Locations

Country	Name	City	State
Australia	Monash Health	Clayton
Australia	Peter MacCallum Cancer Centre	Melbourne
Hong Kong	UNIMED Medical Institute	Hong Kong
Japan	Amagasaki General Medical Center	Amagasaki	Hyogo
Japan	Kyushu Cancer Center	Fukuoka
Japan	Sagara Hospital	Kagoshima
Japan	Kobe City Medical Center General Hospital	Kobe
Japan	Kyoto University Hospital	Kyoto
Japan	Aichi Cancer Center	Nagoya
Japan	Tazuke Kofukai, Medical Research Institute, Kitano Hospital	Osaka
Japan	Saitama Cancer Center	Saitama
Japan	Cancer Institute Hospital Of JFCR	Tokyo
Japan	Kyorin University Hospital	Tokyo
Japan	Tokyo Metropolitan Komagome Hospital	Tokyo
Japan	Toranomon Hospital	Tokyo
Japan	University of Tsukuba Hospital	Tsukuba	Ibaraki
Japan	Kanagawa Cancer Center	Yokohama
Korea, Republic of	National Cancer Center, Korea	Gyeonggi-do
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam
Korea, Republic of	Korea Cancer Center Hospital	Seoul
Korea, Republic of	Seoul National University College of Medicine	Seoul
Taiwan	Changhua Christian Hospital	Changhua
Taiwan	Kaohsiung Medical University Chung-Ho Memorial Hospital	Kaohsiung
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Sun Yat-Sen Cancer Center	Taipei

Sponsors (2)

Lead Sponsor	Collaborator
Kyoto Breast Cancer Research Network	Pfizer

Countries where clinical trial is conducted

Australia,  Hong Kong,  Japan,  Korea, Republic of,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pre-operative Endocrine Prognostic Index (PEPI Score)	The PEPI score is derived from four factors assigned a numerical score following neoadjuvant endocrine therapy, ( including Ki67 expression in the surgical specimen, pathologic tumor size, lymph node status, and estrogen receptor (ER) level).; The PEPI score is the sum of each component score and shows the risk points for relapse-free survival. PEPI=0 means low risk. PEPI= 1 to 3 means intermediate risk .; PEPI more than 4 means high risk.	4 months
Primary	EndoPredict™ EPclin Score	EndoPredict is a multigene test used to predict the risk of distant recurrence of early stage, ER positive ,HER-2 Negative invasive breast cancer. EndoPredict Clinical Score (EP clin ) categorizes patinets into low and high risk groups.Combination of the 12-Gene Molecular Score, tumor stage and lymph node status, generating an EPclin Risk Score.The EPclin Risk Score is calculated, according to the model, as: EPclin Risk Score = (0.35 * tumor size) + (0.64 * lymph node status) + (0.28 * 12-Gene Molecular Score) EPclin Risk Scores from 1.0 through 3.3 shows low risk of recurrencein 10 years.EPclin Risk Scores from 3.4 through 6.0 shows high risk of recurrence in 10 years.	4 months
Secondary	Clinical Response Rate	Observing any reduction in largest tumor diameter on clinical breast examination and ultrasound imaging of breast and axilla after 4 months	4 months
Secondary	Ki67 change	Drop in Ki67 index to less than or equal to 2.7%	4 months
Secondary	pathological response rate	Evaluating the rate of pathological Complete Response based on assessment of surgical specimen	4 months
Secondary	Breast conserving rate	Calculating the rate of breast conserving surgery based on the number of each surgery type	4 months
Secondary	Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment as Assessed by CTCAE v4.03	Type, incidence, severity (as graded by National Cancer Institute - Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03), seriousness and relationship to study medications of adverse events (AE) and any laboratory abnormalities	4 months